Moors & Cabot Inc. Purchases 3,695 Shares of Core Laboratories Inc. $CLB

Moors & Cabot Inc. boosted its position in shares of Core Laboratories Inc. (NYSE:CLB) by 5.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 73,954 shares of the oil and gas company’s stock after buying an additional 3,695 shares during the period. Moors & Cabot Inc.’s holdings in Core Laboratories were worth $852,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Ariel Investments LLC increased its holdings in shares of Core Laboratories by 7.4% during the first quarter. Ariel Investments LLC now owns 10,342,025 shares of the oil and gas company’s stock worth $155,027,000 after buying an additional 709,455 shares in the last quarter. Fred Alger Management LLC grew its position in Core Laboratories by 32.4% during the 1st quarter. Fred Alger Management LLC now owns 736,853 shares of the oil and gas company’s stock worth $11,045,000 after acquiring an additional 180,344 shares during the last quarter. Hotchkis & Wiley Capital Management LLC acquired a new stake in Core Laboratories during the 1st quarter valued at $6,008,000. Envestnet Asset Management Inc. increased its holdings in Core Laboratories by 11.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 282,871 shares of the oil and gas company’s stock valued at $3,259,000 after purchasing an additional 28,866 shares in the last quarter. Finally, Advisors Capital Management LLC raised its position in Core Laboratories by 3.3% in the 1st quarter. Advisors Capital Management LLC now owns 238,867 shares of the oil and gas company’s stock valued at $3,581,000 after purchasing an additional 7,718 shares during the last quarter. 97.81% of the stock is owned by institutional investors.

Core Laboratories Trading Up 0.4%

Shares of CLB opened at $15.35 on Friday. The stock’s fifty day simple moving average is $13.07 and its 200-day simple moving average is $12.08. The firm has a market capitalization of $714.46 million, a PE ratio of 22.90, a price-to-earnings-growth ratio of 8.45 and a beta of 1.40. Core Laboratories Inc. has a 12-month low of $9.72 and a 12-month high of $21.76. The company has a quick ratio of 1.76, a current ratio of 2.37 and a debt-to-equity ratio of 0.41.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, October 22nd. The oil and gas company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.03. The firm had revenue of $134.52 million during the quarter, compared to analyst estimates of $130.92 million. Core Laboratories had a return on equity of 12.85% and a net margin of 6.21%.The company’s revenue was up .1% on a year-over-year basis. During the same period last year, the company earned $0.25 earnings per share. Core Laboratories has set its Q4 2025 guidance at 0.180-0.22 EPS. As a group, research analysts predict that Core Laboratories Inc. will post 0.96 earnings per share for the current year.

Core Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 24th. Shareholders of record on Monday, November 3rd will be given a dividend of $0.01 per share. The ex-dividend date is Monday, November 3rd. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. Core Laboratories’s payout ratio is presently 5.97%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wall Street Zen upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, July 26th. Stifel Nicolaus reduced their price target on shares of Core Laboratories from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, July 16th. Weiss Ratings upgraded shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 24th. Finally, Zacks Research raised shares of Core Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Four analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $12.50.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.